DK123484B - Analogifremgangsmåde til fremstilling af 1H-imidazo[4,5-β]pyrazin-2-oner. - Google Patents
Analogifremgangsmåde til fremstilling af 1H-imidazo[4,5-β]pyrazin-2-oner.Info
- Publication number
- DK123484B DK123484B DK379768AA DK379768A DK123484B DK 123484 B DK123484 B DK 123484B DK 379768A A DK379768A A DK 379768AA DK 379768 A DK379768 A DK 379768A DK 123484 B DK123484 B DK 123484B
- Authority
- DK
- Denmark
- Prior art keywords
- pyrazin
- imidazo
- ones
- preparation
- analogous process
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65904267A | 1967-08-08 | 1967-08-08 | |
US72803368A | 1968-05-09 | 1968-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK123484B true DK123484B (da) | 1972-06-26 |
Family
ID=27097746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK379768AA DK123484B (da) | 1967-08-08 | 1968-08-07 | Analogifremgangsmåde til fremstilling af 1H-imidazo[4,5-β]pyrazin-2-oner. |
Country Status (11)
Country | Link |
---|---|
US (1) | US3507866A (da) |
AT (1) | AT291247B (da) |
BE (1) | BE719154A (da) |
CH (1) | CH516574A (da) |
DE (1) | DE1795062A1 (da) |
DK (1) | DK123484B (da) |
ES (1) | ES356976A1 (da) |
FR (2) | FR1578366A (da) |
GB (1) | GB1193035A (da) |
IL (1) | IL30463A0 (da) |
NL (1) | NL6810650A (da) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
US6903105B2 (en) * | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
US20050090505A1 (en) * | 2003-08-18 | 2005-04-28 | Johnson Michael R. | Methods of reducing risk of infection from pathogens |
US7745442B2 (en) * | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
US20090253714A1 (en) * | 2003-08-20 | 2009-10-08 | Johnson Michael R | Methods of reducing risk of infection from pathogens |
US7923041B2 (en) * | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
US20070021439A1 (en) * | 2005-07-25 | 2007-01-25 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers |
US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
PT2583970E (pt) * | 2006-08-02 | 2016-02-08 | Cytokinetics Inc | Certas entidades químicas, composições e métodos compreendendo imidazopirimidinas |
CN101522681B (zh) * | 2006-08-02 | 2012-10-03 | 赛特凯恩蒂克公司 | 特定的化学个体、组合物和方法 |
KR20140104060A (ko) * | 2006-10-19 | 2014-08-27 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도 |
EP2139478A4 (en) * | 2007-03-30 | 2010-05-05 | Cytokinetics Inc | CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
RU2557242C2 (ru) | 2009-10-26 | 2015-07-20 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способы получения и очистки гетероарильных соединений |
AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
EA201791043A1 (ru) | 2011-07-13 | 2017-09-29 | Сайтокинетикс, Инк. | Комбинированная терапия бокового амиотрофического склероза |
CA2852921C (en) | 2011-10-19 | 2023-10-10 | Signal Pharmaceuticals, Llc | Treatment of cancer with tor kinase inhibitors |
BR112014013332B1 (pt) | 2011-12-02 | 2022-09-06 | Signal Pharmaceuticals, Llc | Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso |
AU2013202305B2 (en) | 2012-02-24 | 2015-03-12 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
BR112015014349A2 (pt) | 2012-12-17 | 2017-07-11 | Parion Sciences Inc | derivados de cloro-pirazina carboxamida úteis para o tratamento de doenças favorecidas por hidratação mucosa insuficiente |
BR112015014178A2 (pt) | 2012-12-17 | 2017-07-11 | Parion Sciences Inc | compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida |
CA2897985A1 (en) | 2013-01-16 | 2014-07-24 | Signal Pharmaceuticals, Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
NZ629469A (en) | 2013-04-17 | 2017-05-26 | Signal Pharm Llc | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
CN105392499B (zh) | 2013-04-17 | 2018-07-24 | 西格诺药品有限公司 | 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法 |
TWI656875B (zh) | 2013-04-17 | 2019-04-21 | 美商標誌製藥公司 | 藉二氫吡并吡治療癌症 |
CA2909625C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
ES2744198T3 (es) | 2013-04-17 | 2020-02-24 | Signal Pharm Llc | Formulaciones farmacéuticas, procesos, formas sólidas y procedimientos de uso relacionados con 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3, 4 dihidropirazino[2,3-b]pirazin-2(1H)-ona |
CN105339008A (zh) | 2013-04-17 | 2016-02-17 | 西格诺药品有限公司 | 用于治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯酰胺的组合疗法 |
CA2908353C (en) | 2013-04-17 | 2021-11-02 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
US9604939B2 (en) | 2013-05-29 | 2017-03-28 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use |
US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
ES2823756T3 (es) | 2014-04-16 | 2021-05-10 | Signal Pharm Llc | Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR |
US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
CA2955009A1 (en) | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
ES2959860T3 (es) | 2017-06-22 | 2024-02-28 | Celgene Corp | Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B |
-
1968
- 1968-05-09 US US728033A patent/US3507866A/en not_active Expired - Lifetime
- 1968-07-26 NL NL6810650A patent/NL6810650A/xx unknown
- 1968-07-29 IL IL30463A patent/IL30463A0/xx unknown
- 1968-08-05 GB GB37296/68A patent/GB1193035A/en not_active Expired
- 1968-08-05 DE DE19681795062 patent/DE1795062A1/de active Pending
- 1968-08-06 ES ES356976A patent/ES356976A1/es not_active Expired
- 1968-08-06 AT AT768868A patent/AT291247B/de not_active IP Right Cessation
- 1968-08-07 BE BE719154D patent/BE719154A/xx unknown
- 1968-08-07 CH CH1183068A patent/CH516574A/de not_active IP Right Cessation
- 1968-08-07 DK DK379768AA patent/DK123484B/da unknown
- 1968-08-08 FR FR1578366D patent/FR1578366A/fr not_active Expired
- 1968-11-08 FR FR173159A patent/FR8409M/fr not_active Expired
Also Published As
Publication number | Publication date |
---|---|
AT291247B (de) | 1971-07-12 |
BE719154A (da) | 1969-02-07 |
GB1193035A (en) | 1970-05-28 |
FR8409M (da) | 1971-03-31 |
NL6810650A (da) | 1969-02-11 |
FR1578366A (da) | 1969-08-14 |
US3507866A (en) | 1970-04-21 |
IL30463A0 (en) | 1968-09-26 |
DE1795062A1 (de) | 1972-03-30 |
ES356976A1 (es) | 1970-10-16 |
CH516574A (de) | 1971-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK123484B (da) | Analogifremgangsmåde til fremstilling af 1H-imidazo[4,5-β]pyrazin-2-oner. | |
DK122885B (da) | Analogifremgangsmåde til fremstilling af 1,4-dihydropyridinderivater. | |
DK121857B (da) | Analogifremgangsmåde til fremstilling af 11β-alkyloxy-13β-alkylgona-1,3,5,(10)-trienderivater. | |
DK119878B (da) | Analogifremgangsmåde til fremstilling af 2-methyl-3-carboxylsyreamido-quinoxalin-di-N-oxider-(1,4). | |
DK118820B (da) | Analogifremgangsmåde til fremstilling af derivater af 5-nitro-2-furyl-isoxazoliner. | |
DK118877B (da) | Analogifremgangsmåde til fremstilling af 3,1-benzoxazin-2-oner. | |
DK123868B (da) | Analogifremgangsmåde til fremstilling af 3-hydroxycumarin-derivater. | |
DK129234B (da) | Fremgangsmåde til fremstilling af levo-1-n-butyl-2',6'-pipecoloxylidid. | |
DK118288B (da) | Analogifremgangsmåde til fremstilling af 2-halogenmethyl-3-carboxylsyreamido-quinoxalin-di-N-oxider-(1,4). | |
DK123232B (da) | Analogifremgangsmåde til fremstilling af 3-alkoxy-17α-propinylestra-1,3,5(10)-trien-17β-oler. | |
DK118246B (da) | Analogifremgangsmåde til fremstilling af 2-isothiuroniummethyl-3-carboxylsyreamido-quinozalin-di-N-oxid-(1,4)-halogenider. | |
DK125464C (da) | Analogifremgangsmåde til fremstilling af 6-halogen-15β, 16β-methylen-pregnanderivater. | |
DK119166B (da) | Fremgangsmåde til fremstilling af 1,4-bezodiazepinderivater. | |
DK128811B (da) | Analogifremgangsmåde til fremstilling af 14α,17α-methylendioxypregnanderivater. | |
DK119559B (da) | Analogifremgangsmåde til fremstilling af 4-pyrimidyl-1,4-dihydropyridinderivater. | |
DK121436B (da) | Analogifremgangsmåde til fremstilling af 14α,17α-methylendioxypregnanderivater. | |
DK118291B (da) | Analogifremgangsmåde til fremstilling af 10α-alkoxy-9,10-dihydroergolinderivater. | |
DK124882B (da) | Analogifremgangsmåde til fremstilling af 17α-acyloxy-11β-methyl-19-norpregn-4-en-3,20-dioner. | |
DK126936B (da) | Fremgangsmåde til fremstilling af 3-oxo-13β-alkylgona-4,9,11-triener. | |
DK121372B (da) | Analogifremgangsmåde til fremstilling af 17β-(1-alkoxycycloalkyloxy)-2α,3α-epithio-5α-androstaner. | |
DK137494B (da) | Fremgangsmåde til fremstilling af 1,4-benzodiazepinderivater. | |
DK120994B (da) | Analogifremgangsmåde til fremstilling af N,N-dimethylaminoætyl-14β-hydroksy-5β-pregn-20-en-21-karboksylater. | |
DK121440B (da) | Analogifremgangsmåde til fremstilling af 2,4-bis-morpholino- eller-thiomorpholino-5-carbalkoxy-pyrimidiner. | |
DK122175B (da) | Analogifremgangsmåde til fremstilling af 3-oxo-13β-alkyl-17α-allyl-17β-hydroxygona-4,9,11-triener. | |
DK121235B (da) | Fremgangsmåde til fremstilling af 1,4-benzodiazepinderivater. |